Company / EPS (Basic)
Amphstar Pharmaceuticals, Inc. EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$2.85
FY2025
5-year range
$0.03 / $2.85
FY2021-FY2025
Trend
+51.6%
vs FY2024
Sector context
#17 of 208
Health Care
What the data says
Among 208 Health Care companies, Amphstar Pharmaceuticals, Inc. is in the top 8% for eps (basic). EPS (Basic) has increased for 3 consecutive years, from $0.03 in FY2022 to $2.85 in FY2025.
Based on SEC 10-K filings.
2.85 in FY2025 with a 3-year CAGR of +356.3%. Top quartile in the Health Care sector.
Improved from $1.30 to $2.85 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- +356.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 208This company $2.85 Sector average -$0.87
▼
+427.4% above sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s eps (basic) has grown for 3 consecutive years.
- In FY2025, eps (basic) increased 51.6% year-over-year.
- Ranks #17 out of 208 companies in the Health Care sector.
- Lowest eps (basic) in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.85 | +51.6% |
| FY2024 | $1.88 | +44.6% |
| FY2023 | $1.30 | +4233.3% |
| FY2022 | $0.03 | -97.1% |
| FY2021 | $1.04 | +966.7% |
| FY2020 | -$0.12 | -250.0% |
| FY2019 | $0.08 | -63.6% |
| FY2018 | $0.22 | +466.7% |
| FY2017 | -$0.06 | +76.0% |
| FY2016 | -$0.25 | -180.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026